Is licofelone, a dual inhibitor of cyclo-oxygenase and 5-lipoxygenase, a promising alternative in anti-inflammatory therapy?

Fundamental and Clinical Pharmacology

Volumn 18, Issue 1, 2004, Pages 125-130

  Bannwarth, Bernard ^a  

^a HÔPITAL PELLEGRIN   (France)

Author keywords

5 lipoxygenase; Cyclo oxygenase; Licofelone; Nonsteroidal anti inflammatory drugs

Indexed keywords

ANTIINFLAMMATORY AGENT; ARACHIDONATE 5 LIPOXYGENASE; BENOXAPROFEN; ICOSANOID; LICOFELONE; LIPOXYGENASE INHIBITOR; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTAGLANDIN SYNTHASE; PROSTAGLANDIN SYNTHASE INHIBITOR; TEBUFELONE; TEPOXALIN;

ANALGESIA; ANTIINFLAMMATORY ACTIVITY; ANTIPYRETIC ACTIVITY; ARTICLE; CLINICAL TRIAL; DATA ANALYSIS; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG EFFICACY; DRUG POTENCY; DRUG SAFETY; DRUG TOLERABILITY; ENZYME INHIBITION; GASTROINTESTINAL TOXICITY; HUMAN; IC 50; LIVER TOXICITY; NEPHROTOXICITY; NONHUMAN; OSTEOARTHRITIS; PRIORITY JOURNAL; STOMACH MUCOSA; STOMACH ULCER;

ACETIC ACIDS; ANALGESICS, NON-NARCOTIC; ANIMALS; ANTI-INFLAMMATORY AGENTS; ARACHIDONATE 5-LIPOXYGENASE; CLINICAL TRIALS; CYCLOOXYGENASE INHIBITORS; DIGESTIVE SYSTEM; EICOSANOIDS; HUMANS; KIDNEY FUNCTION TESTS; LIPOXYGENASE INHIBITORS; OSTEOARTHRITIS; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; PYRROLES; RANDOMIZED CONTROLLED TRIALS;

EID: 1042276537     PISSN: 07673981     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1472-8206.2003.00217.x     Document Type: Article

References (30)

1. Bannwarth B. Anti-inflammatoires non stéroïdiens inhibiteurs sélectifs de la cyclo-oxygénase-2 et lésions gastroduodénales. Presse Med. (2002) 31 1469-1475.
2. McMurray R.W., Hardy K.J. COX-2 inhibitors: today and tomorrow. Am. J. Med. Sci. (2002) 323 181-189.
3. Bombardier C., Laine L., Reicin A. et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N. Engl. J. Med. (2000) 343 1520-1528.
4. Ray W.A., Stein C.M., Daugherty J.R., Hall K., Arbogast P.G., Griffin M.R. COX-2 selective non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease. Lancet (2002) 360 1071-1073.
5. Whittle B.J.R. Gastrointestinal effects of nonsteroidal anti-inflammatory drugs. Fundam. Clin. Pharmacol. (2003) 17 301-313.
6. Parente L. Pros and cons of selective inhibition of cyclooxygenase-2 versus dual lipoxygenase/cyclooxygenase inhibition: is two better than one? J. Rheumatol. (2001) 28 2375-2382.
7. Nickerson-Nutter C.L., Medvedeff E.F. The effects of leukotriene synthesis inhibitors in models of acute and chronic inflammation. Arthritis Rheum. (1996) 39 515-521.
8. Celotti F., Laufer S. Anti-inflammatory drugs: new multitarget compounds to face an old problem. The dual inhibition concept. Pharmacol. Res. (2001) 43 429-436.
9. Murray M.D., Brater D.C. Renal toxicity of the nonsteroidal anti-inflammatory drugs. Annu. Rev. Pharmacol. Toxocol. (1993) 32 435-465.
10. Gambaro G. Strategies to safely interfere with prostanoid activity while avoiding adverse renal effects: could COX-2 and COX-LOX dual inhibition be the answer? Nephrol, Dial. Transplant. (2002) 17 1159-1162.
11. Laufer S.A., Augustin J., Dannhardt G. et al. (6,7- Diaryldihydropyrrolizin-5-yl)acetic acids, a novel class of potent dual inhibitors of both cyclooxygenase and 5-lipoxygenase. J. Med. Chem. (1994) 37 1894-1897.
12. Laufer S., Tries S., Augustin G., Dannhardt G. Pharmacological profile of a new pyrrolizine derivative inhibiting the enzymes cyclooxygenase and 5-lipoxygenase. Arzneimittelforschung (1994) 44 629-636.
13. Anonymous, ML-3000. Drugs of the Future. (1995) 20 1007-1009.
14. Tries S., Neupert W., Laufer S. The mechanism of action of the new antiinflammatory compound ML-3000: inhibition of 5-LOX and COX-1/2. Inflamm. Res. (2002) 51 135-143.
15. Tries S., Laufer S., Radziwon P., Breddin H.K. Antithrombotic and platelet function inhibiting effects of ML3000. a new antiinflammatory drug with COX/5-LOX inhibitory activity. Inflamm. Res. (2002) 51 129-134.
16. Gay R.E., Neidhart M., Pataki F., Tries S., Laufer S., Gay S. Dual inhibition of 5-lipoxygenase and cyclo-oxygenases 1 and 2 by ML3000 reduces joint destruction in adjuvant arthritis. J. Rheumatol. (2001) 28 2060-2065.
17. Jovanovic D.V., Fernandes J.C., Martel-Pelletier J. et al. In vivo inhibition of cyclooxygenase and lipoxygenase by ML-3000 reduces the progression of experimental osteoarthritis. Suppression of collagenase 1 and lnterleukin-1β synthesis. Arthritis Rheum. (2001) 44 2320-2330.
18. Abraham W.M., Laufer S., Tries S. The effects of ML3000 on antigen-induced responses in sheep. Pulm. Pharmacol. Ther. (1997) 10 167-173.
19. Boileau C., Martel-Pelletier J., Jouzeau J.Y. et al. Licofelone (ML-3000), a dual inhibitor of 5-lipoxygenase and cyclooxygenase, reduces the level of cartilage chondrocyte death in vivo in experimental dog osteoarthritis: inhibition of pro-apoptotic factors. J. Rheumatol. (2002) 29 1446-1453.
20. Algate D.R., Augustin J., Atterson P.R. et al. General pharmacology of [2,2-dimethyl-6-(4-chlorophenyl)-7-phenyl-2.3-dihydro-1H-pyrroziline-5-yl) -acetic acid in experimental animals. Arzneimittelforschung (1995) 45 159-165.
21. Wallace J.L., Carter L., McKnight W., Tries S., Laufer S. ML3000 reduces gastric prostaglandin synthesis without causing mucosal injury. Eur. J. Pharmacol. (1994) 271 525-531.
22. Fiorucci S., Distrutti E., de Lima O.M. et al. Relative contribution of acetylated cyclo-oxygenase (COX)-2 and 5-lipooxygenase (LOX) In regulating gastric mucosal integrity and adaptation to aspirin. FASEB J. (2003) 17 1171-1173.
23. Albrecht W., Bias P., Lammerich A. et al. Pharmacokinetics, safety and tolerability of licofelone (ML3000) 200 mg b.i.d. given with food in young and elderly healthy volunteers. Ann. Rheum. Dis. (2002) 61(Suppl. 1) 422.
24. Albrecht W., Bias P., Lammerich A. Investigation of the single dose pharmacoklnetics of warfarin during repeated administration of licofelone (ML3000) 200 mg b.i.d. to healthy volunteers. Ann. Rheum. Dis. (2002) 61(Suppl. 1) 423.
25. Klesser B., Bias P., Buchner A. Licofelone (ML3000), an inhibitor of COX-1, COX-2 and 5-LOX, has little or no effect on the gastric mucosa after 4 weeks of treatment. Ann. Rheum. Dis. (2002) 61(Suppl. 1) 130.
26. Reginster J., Bias P., Buchner A. First clinical results of Iicofelone (ML3000), an inhibitor of COX-1, COX-2 and 5-LOX, for the treatment of osteoarthritis. Ann. Rheum. Dis. (2002) 61(Suppl. 1) 116.
27. Blanco F.J., Buchner A., Bias P., Lammerich A., Schultz U. Licofelone, an inhibitor of COX-1, COX-2 and 5-LOX, is as effective as naproxen and shows improved safety during 12 months of treatment in patients with osteoarthritis of the knee. Ann. Rheum. Dis. (2003) 62(Suppl. 1) 262.
28. Pavelka K., Bias P., Buchner A., Lammerich A., Schultz U. Licofelone, an inhibitor of COX-1, COX-2 and 5-LOX, is as effective as celecoxib and shows improved tolerability during 12 weeks of treatment in patients with osteoarthritis of the knee. Ann. Rheum. Dis. (2003) 62(Suppl. 1) 261.
29. Skelly M.M., Hawkey C.J. Potential alternatives to COX-2 inhibitors. New molecules may overtake the COX-2 inhibitors debate. Br. Med. J. (2002) 324 1289-1290.
30. Langman M.J.S. Adverse effects of conventional non-steroidal anti-inflammatory drugs on the upper gastrointestinal tract. Fundam. Clin. Pharmacol. (2003) 17 393-403.